Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serratamolide
- Development stage
- Preclinical
- Modality
- Small Molecules, Peptides
01
Overview
AT514, also known as serratamolide, is a natural cyclic depsipeptide derived from the bacterium *Serratia marcescens*. It is currently being investigated as a potential antineoplastic agent, particularly for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and breast cancer. The compound exerts its effects by inducing cell cycle arrest and triggering the intrinsic apoptotic pathway. Mechanistically, AT514 interferes with survival signaling mediated by phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC), while also decreasing the activity of the transcription factor NF-κB. As a research-stage compound, it demonstrates selective toxicity toward malignant cells, with an average IC50 of 13 μM in B-CLL cells.
- Other names
- serratamolide
02
Targets
NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)PKC (Protein kinase C family)
Beyond the preview
Go deeper on serratamolide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serratamolide.